MARKET

CUE

CUE

Cue Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.63
-0.34
-3.10%
Closed 16:00 07/29 EDT
OPEN
11.01
PREV CLOSE
10.97
HIGH
11.29
LOW
10.55
VOLUME
234.72K
TURNOVER
--
52 WEEK HIGH
22.49
52 WEEK LOW
9.87
MARKET CAP
333.92M
P/E (TTM)
-7.0890
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 11:48
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows.
Benzinga · 07/13 15:40
Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Chinnapong/iStock via Getty Images Massachusetts-based clinical-stage Cue Biopharma (CUE) announced the dosing of the first patient in Part B expansion phase of its Phase 1 study for CUE-101 as monotherapy at the
Seekingalpha · 06/10 12:38
BRIEF-Cue Biopharma Announces First Patient Dosed In Part B Patient Expansion Of Cue-101 Phase 1 Monotherapy Trial In Hpv+ Second Line And Beyond Hnscc
reuters.com · 06/10 12:14
Cue Biopharma's (NASDAQ:CUE) Stock Price Has Reduced 53% In The Past Year
Cue Biopharma, Inc. ( NASDAQ:CUE ) shareholders should be happy to see the share price up 15% in the last month. But...
Simply Wall St. · 05/24 06:18
Cue Biopharma Posts Narrower Q1 Loss, Higher Revenue
MT Newswires · 05/18 06:30
BRIEF-Cue Biopharma Posts Quarterly Loss Per Share Of $0.41
reuters.com · 05/17 20:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CUE. Analyze the recent business situations of Cue Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CUE stock price target is 30.00 with a high estimate of 33.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 19.08M
% Owned: 60.75%
Shares Outstanding: 31.41M
TypeInstitutionsShares
Increased
31
1.70M
New
6
290.42K
Decreased
33
1.78M
Sold Out
14
713.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Independent Director
Frank Morich
President/Chief Scientific Officer
Anish Suri
Chief Executive Officer/Director
Daniel Passeri
Chief Financial Officer
Kerri-Ann Millar
Senior Vice President/General Counsel/Secretary
Colin Sandercock
Other
Kenneth Pienta
Director
Tamar Howson
Independent Director
Frederick Driscoll
Independent Director
Aaron Fletcher
Independent Director
Cameron Gray
Independent Director
Peter Kiener
Independent Director
Barry Simon
No Data
About CUE
Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Webull offers kinds of Cue Biopharma Inc stock information, including NASDAQ:CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.